Qiao Liu

664 total citations
44 papers, 398 citations indexed

About

Qiao Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Qiao Liu has authored 44 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Economics and Econometrics. Recurrent topics in Qiao Liu's work include Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (15 papers) and Economic and Financial Impacts of Cancer (12 papers). Qiao Liu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (15 papers) and Economic and Financial Impacts of Cancer (12 papers). Qiao Liu collaborates with scholars based in China, Australia and United States. Qiao Liu's co-authors include Xiaohui Zeng, Chongqing Tan, Xia Luo, Lidan Yi, Zhen Zhou, Xiaomin Wan, Liubao Peng, Peng Ye, Sini Li and Liting Wang and has published in prestigious journals such as PLoS ONE, Journal of Clinical Microbiology and Frontiers in Immunology.

In The Last Decade

Qiao Liu

40 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qiao Liu China 13 274 208 75 62 59 44 398
Lidan Yi China 12 234 0.9× 179 0.9× 86 1.1× 82 1.3× 40 0.7× 29 350
Melissa Pavilack United States 13 158 0.6× 247 1.2× 29 0.4× 39 0.6× 91 1.5× 26 330
Melina E. Marmarelis United States 14 359 1.3× 312 1.5× 18 0.2× 35 0.6× 54 0.9× 61 590
Vishal Navani Canada 11 205 0.7× 172 0.8× 19 0.3× 34 0.5× 24 0.4× 38 338
Claudio Flores Peru 11 278 1.0× 136 0.7× 17 0.2× 60 1.0× 49 0.8× 41 493
Mitchell S. von Itzstein United States 11 222 0.8× 101 0.5× 15 0.2× 40 0.6× 45 0.8× 32 344
Marcela Santos Cavalcanti United States 8 256 0.9× 135 0.6× 11 0.1× 66 1.1× 55 0.9× 14 421
Hye Eun Park South Korea 11 277 1.0× 71 0.3× 19 0.3× 74 1.2× 24 0.4× 30 499
Dinesh de Alwis United States 9 276 1.0× 69 0.3× 28 0.4× 19 0.3× 28 0.5× 19 368
Alec Kacew United States 12 157 0.6× 60 0.3× 19 0.3× 76 1.2× 33 0.6× 25 400

Countries citing papers authored by Qiao Liu

Since Specialization
Citations

This map shows the geographic impact of Qiao Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiao Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiao Liu more than expected).

Fields of papers citing papers by Qiao Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiao Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiao Liu. The network helps show where Qiao Liu may publish in the future.

Co-authorship network of co-authors of Qiao Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Qiao Liu. A scholar is included among the top collaborators of Qiao Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiao Liu. Qiao Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Qiao, et al.. (2024). Association between serum albumin and pulmonary function in adolescents: analyses of NHANES 2007–2012. BMC Pulmonary Medicine. 24(1). 554–554. 1 indexed citations
3.
Ma, Qiong, Qiao Liu, Fu Jin, et al.. (2024). Identification of a biomarker to predict doxorubicin/cisplatin chemotherapy efficacy in osteosarcoma patients using primary, recurrent and metastatic specimens. Translational Oncology. 49. 102098–102098. 1 indexed citations
4.
Wang, Wenjing, et al.. (2024). Plant extracellular vesicles contribute to the amplification of immune signals during systemic acquired resistance. Plant Cell Reports. 44(1). 16–16. 4 indexed citations
5.
Jiang, Pei, et al.. (2024). A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis. Risk Management and Healthcare Policy. Volume 17. 945–953.
6.
Ye, Peng, Liting Wang, Liubao Peng, et al.. (2023). Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Clinical Therapeutics. 45(10). 965–972. 3 indexed citations
7.
Zhang, Xin, et al.. (2023). Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China. Risk Management and Healthcare Policy. Volume 16. 1849–1857. 4 indexed citations
8.
9.
Luo, Xia, Zhen Zhou, Xiaohui Zeng, & Qiao Liu. (2022). The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Frontiers in Pharmacology. 13. 935581–935581. 17 indexed citations
10.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2022). Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology. 13. 778505–778505. 19 indexed citations
11.
Liu, Qiao, Xia Luo, Zhen Zhou, et al.. (2021). PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China. Frontiers in Oncology. 11. 745493–745493. 3 indexed citations
12.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. Advances in Therapy. 38(7). 3962–3972. 12 indexed citations
13.
Wan, Xiaomin, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer. Frontiers in Pharmacology. 12. 12 indexed citations
14.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology. 11. 743765–743765. 4 indexed citations
15.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2020). Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 10(11). e040691–e040691. 8 indexed citations
16.
Zeng, Xiaohui, Xiaomin Wan, Liubao Peng, et al.. (2019). Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 9(12). e031019–e031019. 17 indexed citations
17.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2019). Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis. Clinical Drug Investigation. 40(2). 129–137. 40 indexed citations
18.
Wei, Haifeng, Zhe Liu, Shuna Sun, et al.. (2019). Application of computed tomography‑based radiomics signature analysis in the prediction of the response of small cell lung cancer patients to first‑line chemotherapy. Experimental and Therapeutic Medicine. 17(5). 3621–3629. 25 indexed citations
19.
Liu, Qiao, Guoli Li, Cheng Chen, et al.. (2017). Diagnostic Performance of the GenoType MTBDRplus and MTBDRsl Assays to Identify Tuberculosis Drug Resistance in Eastern China. Chinese Medical Journal. 130(13). 1521–1528. 10 indexed citations
20.
Jiang, Yanping, et al.. (2015). [Simultaneous determination of beta-elemene, curcumol, germacrone and neocurdione in volatile oil of Curcuma phaeocaulis and vinegar products by GC-MS].. PubMed. 40(7). 1311–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lidan Yi Breakdown of academic impact, for papers by Melissa Pavilack Breakdown of academic impact, for papers by Melina E. Marmarelis Breakdown of academic impact, for papers by Vishal Navani Breakdown of academic impact, for papers by Claudio Flores Breakdown of academic impact, for papers by Mitchell S. von Itzstein Breakdown of academic impact, for papers by Marcela Santos Cavalcanti Breakdown of academic impact, for papers by Hye Eun Park Breakdown of academic impact, for papers by Dinesh de Alwis Breakdown of academic impact, for papers by Alec Kacew
Rankless by CCL
2026